The total number of records retrieved from this search are 7. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_5298	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration0.1 PFU	In-vitro result100% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5299	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration0.33 PFU	In-vitro result38% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5300	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration1 PFU	In-vitro result10% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5301	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration3.3 PFU	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5302	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration10 PFU	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5303	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration33 PFU	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5304	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration100 PFU	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340